Combination Therapy With Copanlisib and ABL Tyrosine Kinase Inhibitors Against Philadelphia Chromosome-Positive Resistant Cells

Oncotarget - United States
doi 10.18632/oncotarget.10605
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2011English

Philadelphia Chromosome-Positive Acute Myelocytic Leukemia With French-American-British M2 Morphology, Refractory to Tyrosine Kinase Inhibitors

Tenri Medical Bulletin
2012English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica
Hematology
2015English

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Thyroid
MedicineEndocrinologyMetabolismDiabetes
2010English

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Expressing P190BCR-Abl.

Internal Medicine
Internal MedicineMedicine
2002English

Philadelphia Chromosome-Positive De Novo Acute Myeloid Leukemia Treated With Chemotherapy and Second-Generation Tyrosine Kinase Inhibitor

Cureus
2019English

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Personalized Therapy of Tyrosine Kinase Inhibitors

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2013English

Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients

Hematology Reports
Hematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy